Raaj Medisafe

Which are the latest news on Raaj Medisafe?

Why is Raaj Medisafe India Ltd falling/rising?

As of 05-Sep, Raaj Medisafe India Ltd's stock price is declining at 96.43, down 5.0%. Despite strong long-term gains, recent trends show a short-term decline influenced by sector performance and reduced investor activity.

As of 05-Sep, Raaj Medisafe India Ltd's stock price is falling, currently at 96.43, reflecting a decrease of 5.07 or 5.0%. The stock has been underperforming, having lost 5.94% over the last two days and opening with a loss of 2.46% today. Additionally, it has underperformed its sector by 1.46%. The medical equipment sector, in which Raaj Medisafe operates, has also seen a decline of 3.52%. <BR><BR>Investor participation appears to be waning, as evidenced by a significant drop in delivery volume, which fell by 78.65% compared to the five-day average. Despite these recent challenges, the stock has shown strong performance over longer periods, such as a 36.39% increase over the past month and a 175.44% increase over the last three years. However, the current trend indicates a short-term decline, influenced by both sector performance and reduced investor activity.

Who are in the management team of Raaj Medisafe?

The management team of Raaj Medisafe includes Arpit Bangur (Chairman), Navin Jhawar (Managing Director), and three Independent Directors: Rajesh Kumar Gupta, Vijendra Kumar Sood, and Krishna Jajoo, along with Sachin Sarda (Company Secretary & Compliance Officer).

The management team of Raaj Medisafe includes the following individuals:<BR><BR>1. **Arpit Bangur** - Chairman (Non-Executive)<BR>2. **Rajesh Kumar Gupta** - Independent Director<BR>3. **Vijendra Kumar Sood** - Independent Director<BR>4. **Krishna Jajoo** - Independent Director<BR>5. **Sachin Sarda** - Company Secretary & Compliance Officer<BR>6. **Navin Jhawar** - Managing Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Raaj Medisafe do?

Raaj Medisafe India Ltd manufactures medical disposable devices and operates in the micro cap segment of the packaging industry. As of June 2026, it reported net sales of 29 Cr and a net profit of 2 Cr, with a market cap of INR 155 Cr.

Overview:<BR>Raaj Medisafe India Ltd is engaged in the manufacturing of medical disposable devices and operates within the micro cap segment of the packaging industry.<BR><BR>History:<BR>The company was incorporated in September 1985 under the name Manoj Surgical Industries Limited, which was later changed to Raaj Medisafe India Limited in July 2008. The latest reported quarterly results indicate net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 29 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 2 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 155 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 68.00<BR>- Industry P/E: 112<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 1.10<BR>- Return on Equity: 5.05%<BR>- Price to Book: 3.25<BR><BR>Contact Details:<BR>Address: 106 Sector III, Industrial Area Pithampur Dhar Madhya Pradesh : 454774<BR>Tel: 91-7292-403192<BR>Email: info@medisafeindia.com<BR>Website: http://www.raajmedisafeindia.com

Who are the peers of the Raaj Medisafe?

Raaj Medisafe's peers include Emmbi Industries, Swadeshi Inds, Kaira Can, Hind.Tin Works, AMD Industries, Rollatainers, Barflex Polyfilm, and Mega Flex Plast. Raaj Medisafe has an average management risk, excellent growth, and a 1-year return of 16.65%, which is higher than Hind.Tin Works but lower than Swadeshi Inds.

Peers: The peers of Raaj Medisafe are Emmbi Industries, Swadeshi Inds, Kaira Can, Hind.Tin Works, AMD Industries, Rollatainers, Barflex Polyfilm, and Mega Flex Plast.<BR><BR>Quality Snapshot: Excellent management risk is observed at Swadeshi Inds, while Average management risk is found at Emmbi Industries, Raaj Medisafe, Kaira Can, Hind.Tin Works, and Barflex Polyfilm, and the rest. Good growth is noted at Swadeshi Inds and Mega Flex Plast, while Excellent growth is attributed to Raaj Medisafe, and the rest show Below Average growth. Excellent capital structure is present at Kaira Can and Barflex Polyfilm, while Below Average capital structure is found at Emmbi Industries, Raaj Medisafe, Hind.Tin Works, AMD Industries, Rollatainers, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Swadeshi Inds at 42.31%, while the lowest is Hind.Tin Works at -17.30%. Raaj Medisafe's 1-year return is 16.65%, which is higher than Hind.Tin Works but lower than Swadeshi Inds. Additionally, the six-month return is negative for Hind.Tin Works and AMD Industries.

How big is Raaj Medisafe?

As of 31st August, Raaj Medisafe India Ltd has a market capitalization of 155.00 Cr, with recent net sales of 1.05 Cr and a net profit loss of 0.00 Cr. Shareholder's funds are 46.74 Cr and total assets amount to 121.35 Cr.

As of 31st August, Raaj Medisafe India Ltd has a market capitalization of 155.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Raaj Medisafe reported Net Sales of 1.05 Cr. The Net Profit for the same period was a loss of 0.00 Cr.<BR><BR>The latest annual reporting period shows Shareholder's Funds of 46.74 Cr and Total Assets of 121.35 Cr.

Should I buy, sell or hold Raaj Medisafe India Ltd?

When is the next results date for Raaj Medisafe India Ltd?

The next results date for Raaj Medisafe India Ltd is 12 August 2026.

The next results date for Raaj Medisafe India Ltd is scheduled for 12 August 2026.

Are Raaj Medisafe India Ltd latest results good or bad?

Raaj Medisafe India Ltd's latest results for FY25 are strong, with a 44.2% revenue increase to ₹62.00 crores and a net profit doubling to ₹6.00 crores. However, concerns about a slight decrease in operating margin and a high debt-to-equity ratio suggest potential risks for investors.

Raaj Medisafe India Ltd's latest results for FY25 indicate a strong performance overall, showcasing significant growth and profitability. The company reported an annual revenue of ₹62.00 crores, which is a remarkable increase of 44.2% year-on-year. Additionally, net profit doubled to ₹6.00 crores, reflecting a 100% increase compared to the previous fiscal year. This growth is complemented by an impressive average return on equity (ROE) of 82.82%, highlighting the company's efficiency in generating returns for shareholders.<BR><BR>Despite these positive indicators, there are some concerns to consider. The operating margin has slightly decreased to 12.9% from 14.0% in FY24, indicating some pressure on operational efficiency as the company scales. Moreover, the company operates with a high debt-to-equity ratio of 1.77, which raises questions about its leverage and ability to manage debt, especially as interest costs have also increased.<BR><BR>In summary, while Raaj Medisafe India Ltd has demonstrated exceptional growth and profitability, the high leverage and slight margin pressure warrant careful monitoring. Overall, the results can be viewed as good, but potential investors should be aware of the associated risks.

How has been the historical performance of Raaj Medisafe?

Raaj Medisafe has shown significant growth from March 2019 to March 2025, with net sales increasing from 4.80 Cr to 62.42 Cr and a turnaround from losses to profits in operating profit, profit before tax, and profit after tax. Total assets rose from 13.59 Cr to 68.06 Cr, indicating strong financial recovery and growth.

Answer:<BR>The historical performance of Raaj Medisafe shows significant growth in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Raaj Medisafe's net sales have increased from 4.80 Cr in March 2019 to 62.42 Cr in March 2025, reflecting a robust growth trajectory. Total operating income followed a similar trend, rising from 4.80 Cr in March 2019 to 62.42 Cr in March 2025. The company's operating profit (PBDIT) has also improved, moving from a loss of 0.78 Cr in March 2019 to a profit of 8.83 Cr in March 2025. Profit before tax has shown a positive trend, increasing from a loss of 1.59 Cr in March 2019 to a profit of 5.25 Cr in March 2025, while profit after tax reached 6.13 Cr in March 2025, up from a loss of 1.36 Cr in March 2020. The company's total assets have expanded significantly from 13.59 Cr in March 2020 to 68.06 Cr in March 2025, with total liabilities also increasing from 13.59 Cr to 34.51 Cr during the same period. Cash flow from operating activities remained stable, while cash flow from investing activities showed a negative trend, indicating ongoing investments in growth. Overall, Raaj Medisafe has demonstrated a strong recovery and growth in its financial performance over the years.

Who are the top shareholders of the Raaj Medisafe?

The top shareholders of Raaj Medisafe include Sushen Remedies Private Limited with 19.14%, individual investors with 23.05%, and Ramesh Chand Maheshvari as the highest public shareholder at 2.42%. There are no mutual funds or foreign institutional investors currently holding shares in the company.

The top shareholders of Raaj Medisafe include the promoters, with Sushen Remedies Private Limited holding the largest stake at 19.14%. Additionally, individual investors collectively own 23.05% of the company. The highest public shareholder is Ramesh Chand Maheshvari, who holds 2.42%. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

Is Raaj Medisafe overvalued or undervalued?

As of May 27, 2025, Raaj Medisafe's valuation has improved to very attractive, with strong growth potential indicated by a PE ratio of 17.03, an EV to EBITDA of 15.33, and a PEG ratio of 0.33, making it undervalued compared to peers like Poly Medicure and Blue Jet Health, despite recent underperformance against the Sensex.

As of 27 May 2025, the valuation grade for Raaj Medisafe has moved from attractive to very attractive, indicating a positive shift in its investment appeal. The company is currently undervalued, with a PE ratio of 17.03, an EV to EBITDA of 15.33, and a PEG ratio of 0.33, suggesting strong growth potential relative to its price. <BR><BR>In comparison to peers, Raaj Medisafe's valuation metrics stand out, particularly when contrasted with Poly Medicure, which has a PE ratio of 66.7, and Blue Jet Health at 51.29, both categorized as very expensive. The company's return on equity (ROE) is notably high at 27.28%, further reinforcing its attractive valuation. Despite recent underperformance against the Sensex, with a year-to-date return of -8.43% compared to the Sensex's 5.59%, the long-term performance over three and five years shows significant outperformance, suggesting that the current price presents a compelling buying opportunity.

What is the technical trend for Raaj Medisafe?

As of June 3, 2025, Raaj Medisafe's technical trend is mildly bearish, influenced by daily moving averages and a monthly MACD, despite some mixed signals from the weekly MACD and Bollinger Bands.

As of 3 June 2025, the technical trend for Raaj Medisafe has changed from sideways to mildly bearish. The weekly MACD is bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are mildly bearish, reinforcing the current trend. The Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames, which contrasts with the overall bearish sentiment. The KST is bullish weekly but mildly bearish monthly, while Dow Theory indicates a mildly bearish trend on the weekly chart. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly MACD.

Has Raaj Medisafe declared dividend?

No Dividend History Available